Eledon Pharmaceuticals, Inc.

The momentum for this stock is not very good. Eledon Pharmaceuticals, Inc. is a mediocre stock to choose.

News

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Globe Newswire IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ( Eledon ) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will...\n more…

Eledon Pharmaceuticals completes enrollment for Phase 2 BESTOW trial

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Globe Newswire Enrollment Completed Four Months Ahead of ScheduleIRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ( Eledon ) (NASDAQ: ELDN) today announced that it has successfully...\n more…

Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Decreases By 6.8%

Zolmax Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) saw a large drop in short interest during the month of August. As of August 15th, there was short interest totalling 100,700 shares, a...\n more…

Leerink Partnrs Brokers Lower Earnings Estimates for Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)

Zolmax Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Leerink Partnrs reduced their Q3 2024 earnings estimates for shares of Eledon Pharmaceuticals in a research report issued to clients and...\n more…

Leerink Partnrs Research Analysts Cut Earnings Estimates for Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)

Ticker Report Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q3 2024 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals...\n more…